Potential near-term commercialization through two synergistic business units: (i) a telehealth platform connecting patients with independent licensed healthcare providers and (ii) a North American network of pharmacy-based pharmaceutical 3D-printing systems for compounding medications, together forming a personalized medicine ecosystem
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced the establishment of PERSONALIZ3D™, an integrated ecosystem that will combine telehealth, pharmaceutical 3D printing, and pharmacy fulfillment to support the delivery of personalized medicines.
PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D Peptides™ initiative into a broader platform that includes additional therapeutic categories and compounded prescriptions, in which personalized doses, combinations, release profiles, and dosage forms are produced through digitally controlled pharmacy workflows with built-in quality assurance and end-to-end traceability, potentially addressing patient needs and enhancing safety and confidence.
The PERSONALIZ3D™ business model is designed to:
A SIGNIFICANT MARKET OPPORTUNITY
Personalized medicine is shifting healthcare from standardized treatments toward therapies tailored to individual patient needs. Grand View Research estimates that the global personalized-medicine market could grow from approximately US$570 billion in 2024 to approximately US$1.2 trillion by 2033.
Peptides represent a timely starting point due to growing interest among patients and healthcare providers across multiple therapeutic areas. In July 2026, the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee made favourable recommendations concerning certain BPC-157-, KPV-, TB-500-, MOTS-C-, Epitalon- and Semax-related bulk drug substances for the Section 503A Bulks List.
PharmaTher believes these recommendations represent a potential regulatory tailwind and support the evaluation of certain peptides as an initial opportunity for PERSONALIZ3D™.
In parallel, the Company will evaluate additional therapeutic categories in which pharmaceutical 3D printing may improve dosing flexibility, convenience, or the overall patient experience.
"PERSONALIZ3D™ is being designed around two synergistic business units: a telehealth platform intended to help generate demand for personalized medicines and a pharmacy-based 3D-printing network intended to satisfy that demand," said Fabio Chianelli, Chief Executive Officer of PharmaTher. "By connecting telehealth access, pharmacy-based production and digital traceability, we believe PERSONALIZ3D™ can provide a differentiated and scalable model for personalized medicines."
https://images.newsfilecorp.com/files/11479/309111_personaliz3d.jpg
FROM INITIAL COMMERCIAL FOOTPRINT TO A SCALABLE DISTRIBUTED NETWORK
PharmaTher plans to advance PERSONALIZ3D™ through three stages:
According to the American Pharmacists Association, there are about 56,000 community-based or retail pharmacies in the United States. Of these, about 7,500 are compounding pharmacies. PharmaTher views this large pharmacy base as a potentially significant market for pharmaceutical 3D-printing systems and recurring services.
PERSONALIZ3D™ will build upon PharmaTher's existing collaboration with Craft Health and its CraftMake™ pharmaceutical 3D-printing system, and may evaluate additional systems to support the Company's goal of enabling personalized medicine through pharmaceutical 3D printing.
BUILDING LONG-TERM RECURRING REVENUE CHANNELS
The PERSONALIZ3D™ business model is designed to generate potential revenue from several parts of the ecosystem:
ABOUT PERSONALIZ3D™
PERSONALIZ3D™ is PharmaTher's planned personalized medicine platform designed to integrate telehealth, pharmaceutical 3D printing and qualified pharmacy fulfillment. The platform focuses on enabling patient-specific therapies, initially including peptides and other therapeutic categories where individualized doses, release profiles or dosage forms may address patient needs. It is structured around two synergistic components: a telehealth-enabled pathway that supports prescription generation by independent licensed healthcare providers, and a pharmacy-based 3D-printing deployment model that enables scalable, on-demand production and fulfillment of personalized medicines.
PERSONALIZ3D™ remains under development and has not commenced commercial operations.
For more information, visit personaliz3d.com.
ABOUT PHARMATHER
PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a life sciences company focused on personalized medicines.
For more information, visit PharmaTher.com.
FOR MORE INFORMATION
Fabio Chianelli
Chairman and Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: PharmaTher.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
This news release contains forward-looking information within the meaning of applicable securities laws. Forward-looking information includes statements regarding the development, launch and commercialization of PERSONALIZ3D™; the expansion of the Company's strategy beyond peptides; the development and launch of a telehealth platform; the selection and operation of a Section 503A pharmacy Center of Excellence; the installation, evaluation and potential deployment of CraftMake™ pharmaceutical 3D-printing systems; the development of personalized formulations, digital printing workflows and pharmacy operating models; the potential sale, lease, subscription or other placement of pharmaceutical 3D-printing systems; the development of a pharmacy-based distribution network; the potential for a broader commercial relationship with Craft Health; the anticipated scalability of the PERSONALIZ3D™ ecosystem; and the potential generation of revenue from platform services, system placements, consumables, software, maintenance, training, support, intellectual property, products and strategic partnerships.
Forward-looking information is based on management's current expectations, estimates, assumptions and beliefs and is subject to a number of known and unknown risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the risk that PERSONALIZ3D™ or any of its components may not be successfully developed, launched or commercialized; that the telehealth platform may not be implemented as planned or may not generate expected demand; that the Company may not secure or maintain relationships with Craft Health, pharmacy partners, healthcare providers or other third parties; that the CraftMake™ system or related workflows may not perform as intended or meet regulatory, technical or commercial requirements; that the Company may not identify or retain suitable pharmacy partners for system placement; and that the anticipated recurring-revenue model may not be achieved or may not be commercially viable.
Additional risks include uncertainties relating to regulatory approvals, interpretations or changes in laws governing telehealth, pharmacy compounding, peptides, bulk drug substances, medical devices, data privacy and healthcare services; the possibility that regulatory authorities may not adopt or implement advisory committee recommendations; competition; intellectual property protection; product liability; cybersecurity and data protection risks; supply chain constraints; and the need for additional financing to fund development and commercialization activities.
Market and industry data referenced in this release are based on third-party sources believed to be reliable but have not been independently verified by the Company. Estimates regarding the number of compounding pharmacies in the United States are approximate and do not represent confirmed qualified partners or customers for the PERSONALIZ3D™ platform.
Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable securities laws, PharmaTher undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company's continuous disclosure filings available on SEDAR+. This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309111
PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D Peptides™ initiative into a broader platform that includes additional therapeutic categories and compounded prescriptions, in which personalized doses, combinations, release profiles, and dosage forms are produced through digitally controlled pharmacy workflows with built-in quality assurance and end-to-end traceability, potentially addressing patient needs and enhancing safety and confidence.
The PERSONALIZ3D™ business model is designed to:
- Connect patients with independent licensed healthcare providers through telehealth;
- Personalize prescribed medicines using pharmaceutical 3D-printing technology;
- Deliver the medicines through qualified pharmacy partners; and
- Scale through a network of pharmacy-based pharmaceutical 3D-printing systems.
A SIGNIFICANT MARKET OPPORTUNITY
Personalized medicine is shifting healthcare from standardized treatments toward therapies tailored to individual patient needs. Grand View Research estimates that the global personalized-medicine market could grow from approximately US$570 billion in 2024 to approximately US$1.2 trillion by 2033.
Peptides represent a timely starting point due to growing interest among patients and healthcare providers across multiple therapeutic areas. In July 2026, the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee made favourable recommendations concerning certain BPC-157-, KPV-, TB-500-, MOTS-C-, Epitalon- and Semax-related bulk drug substances for the Section 503A Bulks List.
PharmaTher believes these recommendations represent a potential regulatory tailwind and support the evaluation of certain peptides as an initial opportunity for PERSONALIZ3D™.
In parallel, the Company will evaluate additional therapeutic categories in which pharmaceutical 3D printing may improve dosing flexibility, convenience, or the overall patient experience.
"PERSONALIZ3D™ is being designed around two synergistic business units: a telehealth platform intended to help generate demand for personalized medicines and a pharmacy-based 3D-printing network intended to satisfy that demand," said Fabio Chianelli, Chief Executive Officer of PharmaTher. "By connecting telehealth access, pharmacy-based production and digital traceability, we believe PERSONALIZ3D™ can provide a differentiated and scalable model for personalized medicines."
PERSONALIZ3D™ — PharmaTher's personalized medicine platform brand intended to combine telehealth, pharmaceutical 3D printing and pharmacy fulfillment.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11479/309111_personaliz3d.jpg
FROM INITIAL COMMERCIAL FOOTPRINT TO A SCALABLE DISTRIBUTED NETWORK
PharmaTher plans to advance PERSONALIZ3D™ through three stages:
- Establish the Center of Excellence
- Launch the PERSONALIZ3D™ telehealth platform
- Scale through pharmacy-system placements
According to the American Pharmacists Association, there are about 56,000 community-based or retail pharmacies in the United States. Of these, about 7,500 are compounding pharmacies. PharmaTher views this large pharmacy base as a potentially significant market for pharmaceutical 3D-printing systems and recurring services.
PERSONALIZ3D™ will build upon PharmaTher's existing collaboration with Craft Health and its CraftMake™ pharmaceutical 3D-printing system, and may evaluate additional systems to support the Company's goal of enabling personalized medicine through pharmaceutical 3D printing.
BUILDING LONG-TERM RECURRING REVENUE CHANNELS
The PERSONALIZ3D™ business model is designed to generate potential revenue from several parts of the ecosystem:
- Telehealth platform;
- 3D-printing system placements, consumables, software access, and ongoing maintenance and support; and
- Product development, sales, and licensing through strategic and commercial partnerships.
ABOUT PERSONALIZ3D™
PERSONALIZ3D™ is PharmaTher's planned personalized medicine platform designed to integrate telehealth, pharmaceutical 3D printing and qualified pharmacy fulfillment. The platform focuses on enabling patient-specific therapies, initially including peptides and other therapeutic categories where individualized doses, release profiles or dosage forms may address patient needs. It is structured around two synergistic components: a telehealth-enabled pathway that supports prescription generation by independent licensed healthcare providers, and a pharmacy-based 3D-printing deployment model that enables scalable, on-demand production and fulfillment of personalized medicines.
PERSONALIZ3D™ remains under development and has not commenced commercial operations.
For more information, visit personaliz3d.com.
ABOUT PHARMATHER
PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a life sciences company focused on personalized medicines.
For more information, visit PharmaTher.com.
FOR MORE INFORMATION
Fabio Chianelli
Chairman and Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: PharmaTher.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
This news release contains forward-looking information within the meaning of applicable securities laws. Forward-looking information includes statements regarding the development, launch and commercialization of PERSONALIZ3D™; the expansion of the Company's strategy beyond peptides; the development and launch of a telehealth platform; the selection and operation of a Section 503A pharmacy Center of Excellence; the installation, evaluation and potential deployment of CraftMake™ pharmaceutical 3D-printing systems; the development of personalized formulations, digital printing workflows and pharmacy operating models; the potential sale, lease, subscription or other placement of pharmaceutical 3D-printing systems; the development of a pharmacy-based distribution network; the potential for a broader commercial relationship with Craft Health; the anticipated scalability of the PERSONALIZ3D™ ecosystem; and the potential generation of revenue from platform services, system placements, consumables, software, maintenance, training, support, intellectual property, products and strategic partnerships.
Forward-looking information is based on management's current expectations, estimates, assumptions and beliefs and is subject to a number of known and unknown risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the risk that PERSONALIZ3D™ or any of its components may not be successfully developed, launched or commercialized; that the telehealth platform may not be implemented as planned or may not generate expected demand; that the Company may not secure or maintain relationships with Craft Health, pharmacy partners, healthcare providers or other third parties; that the CraftMake™ system or related workflows may not perform as intended or meet regulatory, technical or commercial requirements; that the Company may not identify or retain suitable pharmacy partners for system placement; and that the anticipated recurring-revenue model may not be achieved or may not be commercially viable.
Additional risks include uncertainties relating to regulatory approvals, interpretations or changes in laws governing telehealth, pharmacy compounding, peptides, bulk drug substances, medical devices, data privacy and healthcare services; the possibility that regulatory authorities may not adopt or implement advisory committee recommendations; competition; intellectual property protection; product liability; cybersecurity and data protection risks; supply chain constraints; and the need for additional financing to fund development and commercialization activities.
Market and industry data referenced in this release are based on third-party sources believed to be reliable but have not been independently verified by the Company. Estimates regarding the number of compounding pharmacies in the United States are approximate and do not represent confirmed qualified partners or customers for the PERSONALIZ3D™ platform.
Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable securities laws, PharmaTher undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company's continuous disclosure filings available on SEDAR+. This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309111
